A Study of Actonel for the Prevention of Bone Loss - Full Text View

Sponsors and Collaborators:	M.D. Anderson Cancer Center Procter and Gamble
Information provided by:	M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT00452439

Purpose

Primary: To determine whether the use of Actonel decreases the amount of bone loss in Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) patients receiving chemotherapy with high dose steroids.

Secondary: To determine the CR (complete remission) rate in ALL and LL.

Condition	Intervention	Phase
Leukemia Lymphoma	Drug: Actonel (Risedronate)	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Randomized, Double Blinded Study of Actonel for the Prevention of Bone Loss in Patients Receiving High Dose Corticosteroids for the Treatment of Acute Lymphocytic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

Resource links provided by NLM:

MedlinePlus related topics: Cancer Leukemia, Adult Acute Leukemia, Adult Chronic Lymphoma

Drug Information available for: Risedronic acid Risedronate sodium

U.S. FDA Resources

Further study details as provided by M.D. Anderson Cancer Center:

Estimated Enrollment:	80
Study Start Date:	February 2004

Detailed Description:

One of the side effects of using high dose corticosteroids for the treatment of ALL is osteoporosis.

Risedronate is a medication that was designed to help prevent osteoporosis (brittle and weak bones).

Before treatment you will receive a complete physical exam. You will have around 1 tablespoon of blood drawn for blood tests (these tests are in addition to the routine blood tests you will have as part of the treatment for leukemia). You will have a urine sample collected for routine tests. You will also have a bone mineral density test. This test measures the density of the bones in your spine, hip, and total body. The test is similar to having x-rays of your bones taken.

You will be randomly assigned (as in the toss of a coin) to one of two treatment groups. Participants in the first group will be given risedronate (once per week), vitamin D (once per day), and calcium (once per day). All three medications are pills and will be taken by mouth. Participants in the second group will be given placebo (once per week), vitamin D (once per day), and calcium (once per day). All three medications are pills and will be taken by mouth. A placebo is a substance that looks like the study drug but has no active ingredients.

Neither you nor your doctor will know to which group you are assigned. However, if it is needed for your care, the information will be given to your doctor.

Participants in both groups will continue to receive chemotherapy during this study as scheduled. During chemotherapy, you will have around 1 tablespoon of blood drawn every 1-2 weeks for routine blood tests (as part of the standard of care for your treatment of leukemia).

For this study, you will have urine samples collected and repeat bone mineral density tests 6 months, 12 months, 18 months, and 24 months after starting the study drug (or placebo).

If you develop intolerable side effects from the risedronate you will be taken off the study.

This is an investigational study. Risedronate is FDA approved and commercially available. Risedronate will be provided free of charge while you are enrolled in this study. Up to 80 patients will take part in this study.

All will be enrolled at M. D. Anderson.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age greater than or equal to 18 years
Newly diagnosed ALL or LL receiving chemotherapy with augmented BFM, Hyper-CVAD or any variant of hyper-CVAD.
Female patients of childbearing potential (i.e. no hysterectomy, no loss of menses for 12 consecutive months), must be willing to use contraception.
Negative pregnancy test in female patients.
Patients must be enrolled within 6 weeks of starting induction chemotherapy.

Exclusion Criteria:

Hypocalcemia of less than 8.4 (corrected to account for the albumin level, [see Appendix E for formula])
Hypersensitivity to risedronate or other bisphosphonates
Inability to sit or stand upright for at least 30 minutes
Bone density T-score of -2.5 S.D or less.
Renal insufficiency (calculated creatinine clearance <30cc/min,[see Appendix F for formula])
Patients with a 25-hydroxyvitamin D concentration of less than 20 ng/ml and evidence of osteomalacia (low ionized calcium and high intact PTH).
Concomitant use of bisphosphonates, calcitonin, anabolic steroids, or fluoride.
Corrected calcium above 10.2, due to a cause not related to leukemia/lymphoma (i.e. hyperparathyroidism, multiple myeloma).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00452439

Contacts

Contact: Maria E. Cabanillas, MD

713-745-0654

Locations

United States, Texas
U.T.M.D. Anderson Cancer Center	Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Maria E. Cabanillas, MD

Sponsors and Collaborators

M.D. Anderson Cancer Center

Procter and Gamble

Investigators

Principal Investigator:

Maria E. Cabanillas, MD

U.T.M.D. Anderson Cancer Center

More Information

No publications provided

Study ID Numbers:	ID03-0124
Study First Received:	March 23, 2007
Last Updated:	October 24, 2007
ClinicalTrials.gov Identifier:	NCT00452439 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:

Leukemia
Lymphoma
Acute Lymphocytic Leukemia
Lymphoblastic Lymphoma

Actonel
Risedronate
Bone Loss
Osteoporosis

Study placed in the following topic categories:

Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunoproliferative Disorders
Calcium Channel Blockers
Osteoporosis
Bone Density Conservation Agents
Cardiovascular Agents
Lymphoblastic Lymphoma

Leukemia
Lymphatic Diseases
Calcium, Dietary
Lymphoproliferative Disorders
Lymphoma
Acute Lymphoblastic Leukemia
Risedronic acid

Additional relevant MeSH terms:

Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms by Histologic Type
Immunoproliferative Disorders
Molecular Mechanisms of Pharmacological Action
Immune System Diseases
Physiological Effects of Drugs
Calcium Channel Blockers
Bone Density Conservation Agents
Cardiovascular Agents

Pharmacologic Actions
Membrane Transport Modulators
Leukemia
Lymphatic Diseases
Neoplasms
Therapeutic Uses
Lymphoproliferative Disorders
Lymphoma
Risedronic acid

ClinicalTrials.gov processed this record on September 10, 2009